Unspecific peroxygenase (UPO) represents a new type of heme-thiolate 26 enzyme with self-sufficient mono(per)oxygenase activity and many potential 27 applications in organic synthesis. With a view to taking advantage of these 28
INTRODUCTION compounds and ether cleavage (2). Fuelled by catalytic amounts of H2O2, UPO 79
acts as a self-sufficient monooxygenase through a complex catalytic 80 mechanism that joins the reactive intermediates of heme-peroxidases and 81
P450s (the "peroxide shunt" pathway) (7). Moreover, a UPO oxoiron(IV) 82 protoporphyrin radical cation intermediate (UPO compound I) was recently 83 described and proposed as the main active oxygen species involved in the 84 mono(per)oxygenase activity of UPO (9, 10). Thus, UPO may be considered to 85 be the missing link between P450 monooxygenases and heme-peroxidases (7). 86
Despite much biotechnological interest in this enzyme, no protein 87 engineering studies have attempted to adapt its unique features to the 88 requirements of specific biotransformation processes in industrial settings. 89
Moreover, endeavors to gain a better understanding of UPO´s complex 90 mechanism of action are hindered by the absence of tools with which to design 91 mutants. Indeed, the successful adaptation of UPO has been hampered by 92 many of the same bottlenecks that have precluded the engineering of CPO for 93 decades, including several obstacles that prevent successful functional 94 expression of HTPs in heterologous hosts (e.g., different codon usage, 95 cumbersome post-translational modifications, and heme-thiolate prosthetic 96 group attachments (11, 12) . 97 host has been used in the design of high-redox potential laccases (HRPLs) that 106 are active in human blood and to develop chimeric laccases with combined 107
properties (17) (18) (19) (20) . The number of protocols developed for the generation of 108 DNA diversity in yeast is steadily increasing and as such, the in vivo 109 homologous recombination machinery of this host can be used to enrich 110 mutant libraries (21-23). These strategies have helped to extend the study of 111 S. cerevisiae into the fields of synthetic biology and metabolic engineering, 112 highlighting a wide range of potential applications ranging from biofuel 113 production to novel green processes (24) (25) (26) . 114
Here, for the first time we describe the use of directed evolution to 115 produce a soluble, active and highly stable form of UPO in S. cerevisiae. 116
Several fusion genes were tested to increase initial secretion levels, which were 117 then further optimized by iterative rounds of random mutagenesis, DNA 118 recombination and semi-rational strategies. The enzyme's substrate 119 promiscuity was maintained by simultaneously performing a dual high-120 throughput screening (HTS) assay to efficiently explore mutant libraries 121 without altering protein stability. The final mutant produced was 122 comprehensively characterized and exhibited markedly improved kinetic 123
properties, secretion and stability over a range of temperatures, as well as in 124
Colonies containing the whole autonomously replicating vector were selected 160 and subjected to the dual HT-screening assay, and additional re-screening as 161 described in the Supplemental Material and Methods. 162
Second Generation 163
The best mutants obtained from the first generation (1A11 and 3C2) were 164 submitted to error prone PCR (Taq/MnCl2 and Mutazyme II) as well as in vivo 165 DNA shuffling. The mutagenic rates, the PCR conditions and the thermal 166 cycling program employed were the same as those described for the first 167 generation. Mutated PCR products were mixed with the linearized vector (4:1 168 ratio of PCR products:linearized plasmid) and transformed into competent S. 169 cerevisiae cells in order to promote in vivo DNA shuffling. 170
Third Generation 171
The best mutant from the second round of evolution (12C12 mutant) was 172 subjected to 2 different processes. Purification and Biochemical characterization 242 n*-UPO1, the PaDa-I mutant and wtUPO1 were produced, purified and 243 biochemically characterized as described in the Supplemental Material and 244
Methods. 245

RESULTS AND DISCUSSION
246
Point of Departure: Construction of Fusion Genes and Design of HTS-247
Assay 248
The starting point of this study was the cDNA (upo1 gene) coding for the 249 unspecific peroxygenase from Agrocybe aegerita -Accession Nº FM872457-(30, 250 31). This gene encodes a protein of 328 amino acids plus a 43 amino acid 251 signal peptide that directs secretion in A. aegerita. To achieve sufficient 252 expression in the heterologous host in order to begin directed evolution, 253 several constructs were prepared that contained the native signal sequence (n-254 UPO1), the α-factor prepro-leader from S. cerevisiae (α-UPO1) and the evolved 255 α-factor prepro-leader (α*-UPO1). The evolved α-factor prepro-leader (α*) was 256 previously engineered in association with a HRPL, achieving functional levels 257 of expression after 8 rounds of laboratory evolution (18). The α* construct 258 contained V10D-N23K-A87K mutations that boosted the expression of other 259 HRPL genes (17, 32, 20) and that may also enhance UPO1 secretion. The 260 secretion in each of the fusion genes was determined in 96-well plate 261
negligible. While the use of evolved α-factor prepro-leaders as universal 263 peptides for heterologous expression has been proposed (33), this approach 264 appears to work only when signal sequences are switched between proteintemplates with a high degree of sequence identity (as in the case of HRPLs), 266 indicating that they cannot be used in other less related systems. 267
Several substrates were tested to develop a screening assay for directed 268 UPO evolution. These included benzyl alcohol, veratryl alcohol, 5-nitro-1,3-269
ethylbenzothiazoline-6-sulphonic acid) (ABTS) and p-nitro-phenoxy carboxylic 271 acid (pNCA). Given the low levels of UPO1 secretion in microtiter plates, only 272 the ABTS oxidation assay was reliable and stable, with a good signal response 273 and a low level of interference in culture broth. This assay was adjusted for 274 the appropriate substrate concentrations (0.3 and 2 mM of ABTS and H2O2, 275 respectively) and the optimum pH (4.4). After improving secretion levels (from 276 the second round of evolution onwards), a peroxygenase (oxygen transfer) 277 assay using NBD as substrate was also incorporated into the screening 278 protocol to maintain or even improve mono(per)oxygenase activity. UPO 279 converts NBD into 4-nitrocatechol (yellow) via an initial hydroxylation and the 280 subsequent spontaneous release of formic acid. 4-nitrocatechol can be 281 deprotonated at basic pH values to produce a strong red color (34). 282
Microfermentation conditions were optimized to minimize interferences during 283 screening, evaluating several heme sources (δ-aminolevulinic acid, hemine, 284 hemoglobin), the concentration of MgSO4 (a source of structural Mg 2+ ) and the 285 effect of ethanol on membrane permeability, as well as a range of 286
temperatures, stirring rates and periods of incubation (see Supplemental 287
Material and Methods for details). The heme source chosen for UPO expression 288 (hemoglobin) generated unwanted background activity during screening and it 289 was removed from the expression medium in the last rounds of evolution, as 290 secretion was sufficiently high in its absence. Moreover, the coefficient of 291 variance of the assays was reduced by up to 12% in the final cycles of 292 on November 12, 2017 by guest http://aem.asm.org/ Downloaded from evolution due to the stronger activity displayed by the variants. Three 293 consecutive re-screenings were performed to rule out the presence of false 294 positives. To protect UPO stability during the course of the evolution, the T50 295 (temperature at which the enzyme retains 50% of its initial activity after 10 296 min of incubation) was estimated for each mutant studied during the third re-297 screening. 298
Directed Evolution 299
The total activity of UPO1 was improved ~3,250-fold with respect to the 300 parental type after 5 generations (9,000 clones screened) of directed evolution. 301
Moreover, expression levels of ~8 mg/L were achieved with activity values of 302 6,500 ABTS-U/L and 1,300 NBD-U/L. A combination of several error-prone 303 PCR strategies with in vivo DNA recombination protocols, focused domain 304 mutagenesis on the signal peptide and mutational recovery was performed. In 305 the first generation, both the n-UPO1 and α-UPO1 fusion genes were used as 306 starting points to enhance expression by subjecting the complete constructs to 307 random mutagenesis and recombination. Accordingly, 4 mutant libraries were 308 designed using different DNA polymerases and mutational loads, 2 for each 309 construct. Mutants selected after several consecutive re-screenings were 310 derived exclusively from n-UPO1 libraries. The 2 best variants from this round 311 were 1A11 (L67F) and 3C2 (I248V-F311L) with 13-and 9-fold improvements in 312 total activity compared to n-UPO1, respectively (Figure 1, Table S1 ). 313
The mutations of 1A11 and 3C2 were sufficiently distant (L67F of 1A11 314 was located at a distance of 181 residues from I248V in the 3C2 mutant) to 315 permit a suitable crossover event to take place in the next cycle of evolution 316 via the yeast in vivo recombination machinery. Accordingly, in the second 317 generation these 2 variants were subjected to random mutagenesis and in vivo 318 the NBD assay could be incorporated to the screening protocol to measure 324 oxygen transfer activity, thanks to the high levels of secretion observed for the 325 12C12 mutant. The use of the dual-screening assay based on the NBD:ABTS 326 ratio allowed mutant hits to be selected without jeopardizing activity and 327 variants with improved NBD:ABTS ratios to be identified (see below). 328
In the third generation, a dual approach was taken. First, mutant 329 libraries with different mutational spectra were assembled in vivo by IvAM (27), 330 using the 12C12 mutant (including its signal peptide) as a template (Figure  331   1a) . In addition, the signal peptide of 12C12 was subjected to focal 332 mutagenesis by MORPHING (28) in an attempt to enrich the signal peptide in 333 mutations that favor secretion (Figure 1b) . Libraries landscapes revealed a 334 higher tolerance to mutations in the leader than in the whole UPO1 gene. This 335 is consistent with the observation that mutations in the leader only affect 336 secretion whereas mutations at the whole gene level may also modify catalytic 337
properties. The most promising mutant from the IvAM library, I13D3, 338 contained the new V75I mutation, and it displayed a 70-fold total activity 339 improvement with respect to n-UPO1. By focusing mutational loads in the 340 (Figure 1d) . Finally, the V57A mutation 355 was introduced into 2A12 by mutational recovery, giving rise to the final 356 mutant, PaDa-I. 357
Biochemical Characterization 358
Wild-type UPO1 produced homologously by A. aegerita (wtUPO1) and the 359 PaDa-I mutant secreted in S. cerevisiae were purified to homogeneity 360 (Reinheitszahl value (Rz (A418/A280) ~ 2) and characterized biochemically (Table  361 1, Figure S1 ). The average molecular mass measured by MALDI-TOF-MS was 362 51,100 Da for PaDa-I (i.e., ~5,000 Da higher than that of wtUPO1), and the 363 contribution of glycosylation deduced by deglycosylation gels was around 22% 364 for the wild-type and 30% for the mutant (Figure S1 ). S. cerevisiae tends to 365 hyperglycosylate foreign proteins up to levels of ~50%, conferring them with 366 increased stability and protection against proteolytic degradation. The 367 glycosylation of wtUPO1 observed was exclusively dependent on 6 predicted N-368 glycosylation sites (O-glycosylation sites are not described for this enzyme), 369 associated with up to 8 moieties of the high mannose type (30, 35). None of 370 the amino acid substitutions in PaDa-I introduced new glycosylation motifs 371 and thus, the higher sugar content in this mutant may be due to an increaseddescribed in other directed evolution studies in yeast (14, 17). The PaDa-I and 374 wtUPO1 proteins had similar spectroscopic characteristics in the Fe 3+ resting 375 state, both enzymes showing a maximum in the Soret region of around 418 376 nm, and 2 Q-bands at 570 and 540 nm (Figure 2A) . 377
The very weak expression of the parental n-UPO1 in S. cerevisiae 378 (~0.007 mg/L) hampered its purification to homogeneity. To overcome this 379 impediment, we constructed a fusion gene in which the native signal peptide 380 of n-UPO1 was replaced by that obtained after 5 cycles of directed evolution in 381 yeast (n*, containing F12Y-A14V-R15G-A21D mutations). Larger amounts of 382 native UPO1 were produced in S. cerevisiae from the n*-UPO1 fusion gene, 383 which was then purified to homogeneity. This approach allowed us to make an 384 accurate breakdown of the total activity improvement (TAI) in terms of both 385 specific activity and heterologous functional expression (Figure 3) . The 386 product of the n*-UPO1 fusion gene showed similar biochemical 387 characteristics to the PaDa-I mutant in terms of molecular mass, the degree of 388 glycosylation and thermal stability. After large scale fermentation, the PaDa-I 389 protein showed a 3,250-fold TAI compared to the parental n-UPO1 (6,500 390 ABTS-U/L for PaDa-I vs 2 ABTS-U/L for n-UPO1), an improvement that was 391 20-fold higher than that obtained in microtiter plates where stirring conditions 392 and oxygen availability were limiting. The product of n*-UPO1 showed a 27-393 fold TAI with respect to n-UPO1, reflecting the potency of the evolved signal 394 peptide in promoting UPO1 secretion. The breakdown of the TAI value revealed 395 a 1,114-fold increase in functional expression and a 3.6-fold increase in 396 peroxidative activity (using ABTS) with respect to the parental type. Bearing in 397 mind that n* enhanced functional expression 27-fold, there was a further ~41- Table 1 ). Kinetic constants for peroxidative 406 and peroxygenase activities were assayed using several compounds, along with 407 aryl alcohols with different redox potentials ( Table 2 ). The kcat for n*-UPO1 408 expressed in yeast was ~5-fold lower than that of wtUPO1, although both 409
showed similar substrate affinities, with the exception of the Km for H2O2 (2-410 fold lower in n*-UPO1). General differences in protein folding in the 411 heterologous host, particularly those affecting post-translational modifications 412 (e.g., hyperglycosylation), may affect the activity of the recombinant enzyme. efficiencies for all the substrates tested, indicating marked improvements in 417 the activity of UPO1 after each round of evolution. Indeed, a notable 418 improvement in the kcat value was detected when n*-UPO1 was compared with 419
PaDa-I (with increases of 10-9-, 8-and 7-fold for NBD, ABTS, veratryl alcohol 420 and benzyl alcohol, respectively), and these increases accounted for an overall 421 increase in catalytic efficiency: the 18-fold improvement in the kcat/Km for NBD 422 hydroxylation when comparing n*-UPO1 and PaDa-I was 2.2-times greater 423 than that of wtUPO1 (i.e., 700 and 320 mM -1 s -1 for PaDa-I and wtUPO1, 424 respectively). Thus, the dual screening assay used during in vitro evolution 425 (Figure 1, 2B) . This effect 455 was due to the screening assay used during evolution, in which destabilizing 456 mutations were excluded from the evolutionary pathway. 457
The presence of organic co-solvents is required for many of the 458 transformations mediated by UPO. The activity and stability of wtUPO and the 459 PaDa-I mutant were evaluated in the presence of high concentrations of co-460 solvents with different polarities (with a logP ranging from -0.23 to -1.3) and 461 chemical characteristics (Figure 4A, B) . Regardless of the enzyme tested, 462 activity was reduced drastically in the presence of increasing concentrations of 463 co-solvents in the following order: ethanol>DMSO>ACN~methanol>acetone. 464
Activity in co-solvents were estimated by measuring the C50, the concentration 465 of co-solvent at which the enzyme shows 50% of the corresponding activity in 466 buffer. The strongest activity was observed in acetone (C50 values of 10-12%) 467 and the weakest in ethanol and DMSO (C50 ~2%). In terms of stability in co-468 solvents, both enzymes were very stable at concentrations as high as 50% 469 (v/v), with a half-life of over 48 h and some hyper-activation (Figure 4C, D) . 470 heme-thiolate domain, with Arg189 and Glu196 forming the acid-base pair for 500 far from the catalytic site (Figure S2) . At this point, it is important to note that 509 our aim was to improve total activity while conserving enzyme stability. Thus, 510
we can only speculate as to whether a less rigid directed evolution approach 511 would have unmasked other, less conservative substitutions, at the cost of 512 threatening protein stability (40). The 41-fold enhancement in secretion 513 induced by these mutations may be due to tighter folding during the earliest 514 post-translational stages, which ultimately favors protein stability and 515 secretion. The V57A mutation lies in a helix at the surface of the protein next 516 to the N-terminus (Figure 5A, B) . According to our model, the replacement of 517
Val57 with a less bulky residue may compress this region between adjacent 518 prolines (at positions 5 and 6 of the N-terminus) and thereby increasing the 519 protein's robustness. The L67F mutation is located in the vicinity of the 520 catalytic pocket, very close to Phe69 of the Phe triad involved in binding 521 aromatic substrates. This mutation may be partially responsible for the kinetic 522 enhancements observed, since after substitution, the aromatic ring of Phe67 is 523 orientated towards the active site (Figure 5C, D) . The V75I mutation is 524 produced by the substitution of a hydrophobic residue with another slightly 525 larger hydrophobic residue, which may establish new hydrophobic contacts 526 with surrounding residues, thereby favoring protein stability (Figure 5A, B) . 527
Finally, the I248V and F311L mutations are positioned in the surroundings of 528 the heme channel. The I248V mutation is produced by the replacement of 529
Ile248 at the entrance of the channel to the heme cavity with a Val residue, 530 which could favor the access of bulkier substrates (Figure 5E, F) . The F311L 531 mutation is located in front of the heme channel with Phe76 in between. The 532 substitution of Phe with Leu enlarges the cavity, which may in turn have 533 beneficial effects on kinetics (Figure 5A, B) .
Conclusions 536
Since its discovery 10 years ago, the potential use of UPO in 537 applications ranging from chemical processes (including some relevant 538 industrial transformations such as alkane hydroxylations and olefin 539 epoxidations) to the preparation of O-and N-dealkylated human drug 540 metabolites, as well as bioremediation (PAH oxidation) and biosensor 541 development, has been studied exhaustively (41-50). For decades, regio-and 542 enantioselective oxyfunctionalization has been a "forbidden territory" for most 543 biocatalysts, except for P450 monooxygenases. However, unlike the latter, 544
UPO is soluble and requires neither expensive cofactors (NAD[P]H) nor 545 auxiliary flavoproteins. Despite these advantages, the lack of suitable directed 546 evolution platforms with which to enhance UPO´s catalytic properties has 547 limited the exploitation of this versatile biocatalyst. The directed evolution 548 process presented here describes for the first time an attractive pathway 549 through which ad-hoc UPO variants can be tailored for use in several 550 industrial reactions, such as alkanes hydroxylation, and the transformation of 551 benzene into phenol and naphthalene into naphthol (51, 52). 552
The evolved UPO1 variant of this study is very active and stable over a 553 wide temperature range, as well as in the presence of a variety of co-solvent 554 were produced on a large scale and their TAIs measured. The n*-UPO1 and 800
PaDa-I were purified and their specific activities calculated. The n* enhanced 801 functional expression ~27-fold, whereas mutations in mature PaDa-I resulted 802 in a ~120-fold increase in total activity. The 3,250-fold increase in the total 803 activity of PaDa-I was broken down as a 3.6-fold improvement in specific 804 activity and a 1,114-fold improvement in functional expression. 805 
